MGX Metagenomi Technologies, LLC
- 6.570
- -0.600-8.37%
Metagenomi Technologies, LLC News
HC Wainwright & Co. : The Metagenomi (MGX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. : The Metagenomi (MGX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $10 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Metagenomi (NASDAQ:MGX) with a Buy and maintains $10 price target.
Metagenomi Q1 2024 Adj EPS $(1.19) Misses $(0.78) Estimate
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.78) by 52.56 percent.
Metagenomi Technologies, LLC | 10-Q: Quarterly report
Press Release: Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational develo
Metagenomi Initiated at Buy by HC Wainwright & Co.
Metagenomi Initiated at Buy by HC Wainwright & Co.
Metagenomi (MGX.US) was first covered by HC Wainwright & Co., which gave it a buy rating, with a target price of $10.00.
Metagenomi (MGX.US) was first covered by HC Wainwright & Co., which gave it a buy rating, with a target price of $10.00.
HC Wainwright & Co. Initiates Coverage On Metagenomi With Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Metagenomi (NASDAQ:MGX) with a Buy rating and announces Price Target of $10.
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
Thursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an income of $(0.19), smaller than the consensus estimate loss of $(3.55).The company reported sales of $167
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out
Metagenomi Cut to Neutral From Overweight by JP Morgan
Metagenomi Cut to Neutral From Overweight by JP Morgan
JP Morgan Downgrades Metagenomi to Neutral, Lowers Price Target to $6
JP Morgan analyst Brian Cheng downgrades Metagenomi from Overweight to Neutral and lowers the price target from $16 to $6.
Metagenomi, Moderna Terminate Gene Editing Collaboration
Metagenomi to Regain Full Development Rights to Its Wholly-owned Base Editing and RIGS Systems
EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive
12 Health Care Stocks Moving In Friday's After-Market Session
GainersMobile-health Network (NASDAQ:MNDR) shares rose 15.0% to $31.35 during Friday's after-market session. The company's market cap stands at $1.0 billion. Galera Therapeutics (NASDAQ:GRTX) stock in
Metagenomi to Present at Upcoming Scientific Meetings
- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 - Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024 EME
Metagenomi Is Maintained at Buy by Chardan Capital
Metagenomi Is Maintained at Buy by Chardan Capital
Chardan Capital Maintains Buy on Metagenomi, Maintains $21 Price Target
Chardan Capital analyst Geulah Livshits maintains Metagenomi with a Buy and maintains $21 price target.
Metagenomi 2023 Loss Widens, Revenue Rises
Metagenomi (MGX) reported a full-year 2023 loss Wednesday of $20.05 per diluted share, widening from the loss of $12.82 a year earlier. Four analysts surveyed by Capital IQ expected a loss of $4.40. R
Metagenomi Reports FY Results
Analysis
Price Target
No Data
